WuXi NextCODE has raised $240 million in series B, FDA slapped Celltrion with a long Form 483, Biocon's $275 million insulin plant opened shop.

Pfizer is leaning heavily on Celltrion for biosimilar development and manufacturing, but its South Korean partner has stumbled with an FDA inspection.

Four weeks after Germany pulled the manufacturing authorization for a Dr. Reddy’s plant in India, it has blocked a second one.

It’s dance time for Astellas’ new ad campaign. The company has partnered up with the ABC show “Dancing with the Stars” for its newest Myrbetriq push.

Lilly will close its Shanghai R&D center, OrbiMed sets up its third Asia healthcare fund, and Takeda marches into CAR-T with a new deal.

Under mounting pressure in diabetes, Eli Lilly has just become the latest drugmaker to undergo a major shakeup.

China’s 3SBio, in a joint venture with CPE Funds, seeks to buy Canadian CDMO Therapure Biomanufacturing for $290 million pending shareholder approval.

Takeda and AZ will team up on Parkinson’s candidate, Samsung Bioepis got nod for a Humira copycat and Daiichi Sankyo said AZ buyout is “not the fact.”

Pharma Asia